Team:Slovenia/SocietyQuestionnaire
From 2012.igem.org
(8 intermediate revisions not shown) | |||
Line 2: | Line 2: | ||
<head> | <head> | ||
<meta http-equiv="X-UA-Compatible" content="IE=edge" /> | <meta http-equiv="X-UA-Compatible" content="IE=edge" /> | ||
+ | <!-- back to top --> | ||
+ | <div style="position:fixed; bottom:45px; right:30px; width:100px; height:66px; background-color:transparent;"> | ||
+ | <a href="#topofthepage"> | ||
+ | <table style="background-color:transparent;" onclick="window.location = '#topofthepage'" class="invisible" style="height:100%;"> | ||
+ | <tr class="invisible" style="background-color:transparent;"> | ||
+ | <td class="invisible" style="background-color:transparent;" valign="center"> | ||
+ | <img width="100px" src ="https://static.igem.org/mediawiki/2012/1/14/Svn12_hp_btt.png"></img> | ||
+ | </td></tr></table> | ||
+ | </a> | ||
+ | </div> | ||
<style type="text/css"> | <style type="text/css"> | ||
Line 201: | Line 211: | ||
#cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;} | #cssmenu ul li > ul li{display:block; list-style:inside none; padding:0; margin:0; position:relative;} | ||
#cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); } | #cssmenu ul li > ul li a{ outline:none; display:block; position:relative; margin:0; padding:8px 20px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); } | ||
+ | #cssmenu ul li > ul li a table tr td span{ outline:none; display:block; position:relative; margin:0; padding:0px 0px; font:10pt Arial, Helvetica, sans-serif; color:#fff; text-decoration:none; text-shadow:1px 1px 0 rgba(0,0,0, 0.5); } | ||
#cssmenu, #cssmenu > ul > li > ul > li a:hover | #cssmenu, #cssmenu > ul > li > ul > li a:hover | ||
{ background:#043A6B; | { background:#043A6B; | ||
Line 216: | Line 227: | ||
#cssmenu > ul > li > a:hover{background:#0C5DA5;} | #cssmenu > ul > li > a:hover{background:#0C5DA5;} | ||
/* end CSS navigation menu (blue) */ | /* end CSS navigation menu (blue) */ | ||
+ | |||
+ | /*new table start*/ | ||
+ | table.newtable {background-color:transparent;} | ||
+ | td.newtable, th.newtable {background-color:transparent;} | ||
+ | thead.newtable{ } | ||
+ | tbody .newtable{} | ||
+ | /*new table*/ | ||
Line 292: | Line 310: | ||
<body> | <body> | ||
+ | <a name="topofthepage" style="background-color:transparent;"></a> | ||
+ | |||
<div id="banner"> | <div id="banner"> | ||
- | |||
</div> | </div> | ||
Line 316: | Line 335: | ||
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchDesignedTALregulators'><span>Designed TAL regulators</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li> | ||
- | <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li> | + | <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchPositiveFeedbackLoopSwitch';" class="newtable"><tr class="newtable"><td class="newtable"><span>Positive feedback loop switch</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> |
+ | <li><a href='https://2012.igem.org/Team:Slovenia/TheSwitchControls'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TheSwitchControls';" class="newtable"><tr class="newtable"><td class="newtable"><span>Controls</span></td><td class="newtable"><img style="margin-right:-81px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
Line 324: | Line 344: | ||
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsEscapeTag'><span>Escape tag</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/SafetyMechanismsTermination'><span>Termination</span></a></li> | ||
- | + | <li><a href="https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation"><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/SafetyMechanismsMicrocapsuleDegradation';" class="newtable"><tr class="newtable"><td class="newtable"><span>Microcapsule degradation</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | |
</ul> | </ul> | ||
</li> | </li> | ||
Line 332: | Line 352: | ||
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationHepatitisC'><span>Hepatitis C</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationIschaemicHeartDisease'><span>Ischaemic heart disease</span></a></li> | ||
+ | <li><a href='https://2012.igem.org/Team:Slovenia/ImplementationImpact'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ImplementationImpact';" class="newtable"><tr class="newtable"><td class="newtable"><span>Impact</span></td><td class="newtable"><img style="margin-right:-86px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | ||
</ul> | </ul> | ||
Line 339: | Line 360: | ||
<ul> | <ul> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/Modeling'><span>Overview</span></a></li> | ||
- | + | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPK'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingPK';" class="newtable"><tr class="newtable"><td class="newtable"><span>Pharmacokinetics</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | |
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingMethods'><span>Modeling methods</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingMutualRepressorSwitch'><span>Mutual repressor switch</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingPositiveFeedbackLoopSwitch'><span>Positive feedback loop switch</span></a></li> | ||
- | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><span> | + | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingQuantitativeModel';" class="newtable"><tr class="newtable"><td class="newtable"><span>Experimental model</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> |
- | + | <li><a href='https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/ModelingInteractiveSimulations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Interactive simulations</span></td><td class="newtable"><img style="margin-right:-15px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | |
</ul> | </ul> | ||
</li> | </li> | ||
Line 355: | Line 376: | ||
<ul> | <ul> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/Notebook'><span>Experimental methods</span></a></li> | ||
- | + | <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLablog'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/NotebookLablog';" class="newtable"><tr class="newtable"><td class="newtable"><span>Lablog</span></td><td class="newtable"><img style="margin-right:-90px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | |
<li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/NotebookLabSafety'><span>Lab safety</span></a></li> | ||
</ul> | </ul> | ||
Line 378: | Line 399: | ||
<li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/Team'><span>Team members</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/TeamAttributions'><span>Attributions</span></a></li> | ||
+ | <li><a href='https://2012.igem.org/Team:Slovenia/TeamCollaborations'><table onclick="window.location = 'https://2012.igem.org/Team:Slovenia/TeamCollaborations';" class="newtable"><tr class="newtable"><td class="newtable"><span>Collaborations</span></td><td class="newtable"><img style="margin-right:-20px;" width="25px" src="https://static.igem.org/mediawiki/2012/e/ee/Svn12_hp_new.png"></img></td></tr></table></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/TeamGallery'><span>Gallery</span></a></li> | ||
<li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li> | <li><a href='https://2012.igem.org/Team:Slovenia/TeamSponsors'><span>Sponsors</span></a></li> | ||
Line 385: | Line 407: | ||
</div> | </div> | ||
<!-- end main menu --> | <!-- end main menu --> | ||
+ | |||
+ | |||
+ | |||
</div> <!-- end menu --> | </div> <!-- end menu --> | ||
Line 390: | Line 415: | ||
<div id="main"> | <div id="main"> | ||
<br/> | <br/> | ||
+ | |||
+ | <!-- dummy link na bannerju --> | ||
+ | <a href="https://2012.igem.org/Main_Page"> | ||
+ | <div id="dummy" style="background-color:transparent; position:absolute; left:870px; top:25px; width:115px; height:80px; z-index:100; opacity:0.0;"> | ||
+ | </div> | ||
+ | </a> | ||
+ | |||
<!-- VSEBINA OD TU DALJE --> | <!-- VSEBINA OD TU DALJE --> | ||
- | <h1>Questionnaire for patients undergoing therapy for the hepatitis C | + | <h1>Questionnaire for patients undergoing therapy for the hepatitis C</h1> |
<p>We are a student research team, participating in the 2012 iGEM competition and in our project we are developing a new type of a biological drug delivery system as a new treatment possibility.</p> | <p>We are a student research team, participating in the 2012 iGEM competition and in our project we are developing a new type of a biological drug delivery system as a new treatment possibility.</p> | ||
Line 399: | Line 431: | ||
<p>Instructions: Circle the number before the answer that is most true for you. Please answer honestly and skip any questions you do not wish to answer.</p> | <p>Instructions: Circle the number before the answer that is most true for you. Please answer honestly and skip any questions you do not wish to answer.</p> | ||
- | + | ||
- | Age:............... | + | <p>Age:...............</p> |
- | < | + | |
Education: | Education: | ||
<br/> | <br/> | ||
Line 415: | Line 447: | ||
A short description of our project: | A short description of our project: | ||
<br/> | <br/> | ||
- | Biopharmaceuticals are among most effective and most expensive drugs for the treatment of viral hepatitis, diabetes, cancer and other diseases. Standard therapy with biological drugs requires multiple doses, often as daily or weekly injections of the biological drug | + | Biopharmaceuticals are among most effective and most expensive drugs for the treatment of viral hepatitis, diabetes, cancer and other diseases. Standard therapy with biological drugs requires multiple doses, often as daily or weekly injections of the biological drug that is usually obtained from mammalian cell cultures and purified. |
The idea of our project is to use drug producing cells and enclose them in microcapsules that would be administered directly into the target tissue. The therapy would allow for noninvasive regulation under medical supervision. It would be possible to control and eventually destroy the therapeutical cells, when the therapy is no longer needed. | The idea of our project is to use drug producing cells and enclose them in microcapsules that would be administered directly into the target tissue. The therapy would allow for noninvasive regulation under medical supervision. It would be possible to control and eventually destroy the therapeutical cells, when the therapy is no longer needed. | ||
- | We believe this new approach would reduce side effects, since the therapeutic would be continuously | + | We believe this new approach would reduce side effects, since the therapeutic would be continuously synthesized in its target tissue and drug concentrations elsewhere in the body would be lower. |
This kind of therapy would be more efficient and widely available compared to standard treatments in use today. | This kind of therapy would be more efficient and widely available compared to standard treatments in use today. | ||
</p> | </p> | ||
Line 492: | Line 524: | ||
+ | <h2>Online questionnaires (in Slovenian language)</h2> | ||
+ | |||
+ | |||
+ | <p><a href="https://docs.google.com/spreadsheet/viewform?pli=1&formkey=dERKVGR4QkhtSW1qYmRLdTY2Z1ltU3c6MA#gid=0">The questionnaire for journalists</a><p> | ||
+ | <p><a href="https://docs.google.com/spreadsheet/viewform?formkey=dHlEWFRfUXdlVm5VSzFhekt2WEVScmc6MQ">The questionnaire for the general public</a></p> | ||
+ | The questionnaires for the general public and for journalists were the same as for the patients only without questions 2, 5, 6, 9 and 10. The only difference between the questionnaire for journalists and the one for the general public were the questions about personal detailes (course of study, place of employment). | ||
+ | <hr> | ||
+ | <b> | ||
+ | Next: <a href='https://2012.igem.org/Team:Slovenia/Team'>Team >></a> | ||
+ | </b> | ||
<!-- KONEC VSEBINE --> | <!-- KONEC VSEBINE --> |
Latest revision as of 21:03, 26 October 2012
Questionnaire for patients undergoing therapy for the hepatitis C
We are a student research team, participating in the 2012 iGEM competition and in our project we are developing a new type of a biological drug delivery system as a new treatment possibility.
This questionnaire is anonymous and the answers will help us with our project.
Instructions: Circle the number before the answer that is most true for you. Please answer honestly and skip any questions you do not wish to answer.
Age:...............
Education:- Primary school
- High school
- Student
- University education
- PhD
A short description of our project:
Biopharmaceuticals are among most effective and most expensive drugs for the treatment of viral hepatitis, diabetes, cancer and other diseases. Standard therapy with biological drugs requires multiple doses, often as daily or weekly injections of the biological drug that is usually obtained from mammalian cell cultures and purified.
The idea of our project is to use drug producing cells and enclose them in microcapsules that would be administered directly into the target tissue. The therapy would allow for noninvasive regulation under medical supervision. It would be possible to control and eventually destroy the therapeutical cells, when the therapy is no longer needed.
We believe this new approach would reduce side effects, since the therapeutic would be continuously synthesized in its target tissue and drug concentrations elsewhere in the body would be lower.
This kind of therapy would be more efficient and widely available compared to standard treatments in use today.
- Do you understand the description of our project?
Yes
No
Not really, I would like to know more about ....
- Are you receiving treatment with biopharmaceuticals?
Yes
No
Not currently, but I have previously.
- Do you agree that biopharmaceuticals in Slovenia are available to all patients who need them?
Yes
No
I do not know
- Do you believe that the high price limits the use of biopharmaceuticals?
Yes
No
Partially
I do not know
- Are you experiencing any adverse effects because of the interferon treatment?
No side effects
Mild side effects
Strong side effects
I haven't been receiving therapy yet
- How much does the need for the repetitive injections of interferon adversely affect the quality of your life?
Strongly
Medium
Not at all
- Do you think it would be beneficial to develop a therapy with human cells which would produce biological drugs inside the diseased tissue and thus reduce both side effects and the need for frequent drug application?
Yes
No
Maybe
- Which of the following would be most important for you regarding that kind of treatment:
Efficiency
Safety
Price
Ethical considerations
- Would you participate in a clinical study using that kind of therapy?
Yes
No
Maybe
- Would you change your mind if you knew the cells are genetically modified?
Yes
No
- Do you know what synthetic biology is?
Yes
No
I have heard about it
- Do you support the use of synthetic biology for solving health issues and developing biofuels or new materials?
Yes
No
Maybe
- Would you be willing to consume genetically modified food (GM food) that would have better taste, looked more appealing or would be healthier in general?
Yes
No
Maybe
Online questionnaires (in Slovenian language)
The questionnaire for journalists
The questionnaire for the general public
The questionnaires for the general public and for journalists were the same as for the patients only without questions 2, 5, 6, 9 and 10. The only difference between the questionnaire for journalists and the one for the general public were the questions about personal detailes (course of study, place of employment).Next: Team >>